Skip to main content
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. — Investor Relations & Filings

Ticker · XBIO ISIN · US9840155033 LEI · 5493002WV0KYX8JXAH52 US Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2024-08-13 Interim / Quarterly Rep…
Country US United States of America
Listing US XBIO

About Xenetic Biosciences, Inc.

https://www.xeneticbio.com/

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing proprietary technology platforms for immune-oncology. The company's development pipeline is centered on its XCART platform, a personalized CAR T-cell therapy technology, and its DNase-based oncology platform. The DNase platform is designed to improve cancer therapies by targeting Neutrophil Extracellular Traps (NETs), which are implicated in cancer progression, metastasis, and resistance to treatments. Xenetic's research aims to address multiple high-value, difficult-to-treat cancer indications, including pancreatic cancer and other solid tumors.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q2 2024
2024-08-13 English
Delisting Announcement 2024
Delisting Announcement
2024-07-18 English
Director's Dealing 2024
Director's Dealing
2024-06-21 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 18, 2024, by Xenetic Biosciences, Inc. The content focuses on changes in the company's board and senior management, specifically the appointment of an interim CEO, amendments to employment agreements, and separation agreements with former executives. There are no financial statements or detailed financial data presented. The primary subject is management changes, which aligns with the Board/Management Information category (MANG).
2024-06-21 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details changes in the company's board and senior management, including the appointment of an interim CEO and resignations of other officers. There are no financial statements or detailed financial data presented, and the document is not an earnings release or annual/interim report. The key section is Item 5.02, which relates to departure and appointment of directors and officers. Therefore, this filing fits the category of Board/Management Information (MANG). The document length (6201 characters) supports it being a full report rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2024-05-22 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Xenetic Biosciences, Inc. dated May 10, 2024. It announces the results of operations and financial condition for the quarter ended March 31, 2024, and includes a press release as Exhibit 99.1. The document is a current report, not a full quarterly or annual report, and it primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis itself. The length is 6412 characters, which is relatively short and consistent with a current report. The content fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. Therefore, the appropriate classification is Earnings Release (ER).
2024-05-10 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.